company background image

Tyme Technologies NasdaqCM:TYME Stock Report

Last Price


Market Cap







27 Jun, 2022


Company Financials
TYME fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

TYME Stock Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.

Tyme Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tyme Technologies
Historical stock prices
Current Share PriceUS$0.28
52 Week HighUS$2.02
52 Week LowUS$0.22
1 Month Change9.58%
3 Month Change-20.86%
1 Year Change-78.42%
3 Year Change-75.86%
5 Year Change-90.50%
Change since IPO-94.57%

Recent News & Updates

May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.

Shareholder Returns

TYMEUS BiotechsUS Market

Return vs Industry: TYME underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: TYME underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is TYME's price volatile compared to industry and market?
TYME volatility
TYME Average Weekly Movement13.2%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: TYME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: TYME's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

201113Richie Cunningham

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.

Tyme Technologies Fundamentals Summary

How do Tyme Technologies's earnings and revenue compare to its market cap?
TYME fundamental statistics
Market CapUS$49.06m
Earnings (TTM)-US$23.63m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TYME income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.63m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TYME perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is TYME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TYME?

Other financial metrics that can be useful for relative valuation.

TYME key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does TYME's PB Ratio compare to its peers?

TYME PB Ratio vs Peers
The above table shows the PB ratio for TYME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.7x
MBRX Moleculin Biotech
AIMD Ainos
UBX Unity Biotechnology
TYME Tyme Technologies

Price-To-Book vs Peers: TYME is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.7x).

Price to Earnings Ratio vs Industry

How does TYME's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: TYME is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is TYME's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TYME PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TYME's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of TYME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TYME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TYME's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TYME's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Tyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tyme Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Tyme Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Tyme Technologies performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TYME is currently unprofitable.

Growing Profit Margin: TYME is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 9.1% per year.

Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: TYME has a negative Return on Equity (-29.5%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Tyme Technologies's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TYME's short term assets ($78.9M) exceed its short term liabilities ($7.4M).

Long Term Liabilities: TYME's short term assets ($78.9M) exceed its long term liabilities ($546.1K).

Debt to Equity History and Analysis

Debt Level: TYME is debt free.

Reducing Debt: TYME had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TYME has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TYME has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 20.6% each year

Discover healthy companies


What is Tyme Technologies's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TYME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TYME's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TYME has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Richie Cunningham (50 yo)





Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 24, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...

CEO Compensation Analysis

Compensation vs Market: Richie's total compensation ($USD1.85M) is above average for companies of similar size in the US market ($USD749.40K).

Compensation vs Earnings: Insufficient data to compare Richie's compensation with company performance.

Leadership Team

Experienced Management: TYME's management team is considered experienced (2.4 years average tenure).

Board Members

Experienced Board: TYME's board of directors are considered experienced (5.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: TYME insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Tyme Technologies, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Tyme Technologies, Inc.
  • Ticker: TYME
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$49.062m
  • Shares outstanding: 172.21m
  • Website:

Number of Employees


  • Tyme Technologies, Inc.
  • 1 Pluckemin Way
  • Suite 103
  • Bedminster
  • New Jersey
  • 7921
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.